Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320 (Source: J Rheumatol)
Source: J Rheumatol - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320 (Source: J Rheumatol)
Source: J Rheumatol - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320 (Source: J Rheumatol)
Source: J Rheumatol - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320 (Source: J Rheumatol)
Source: J Rheumatol - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320 (Source: J Rheumatol)
Source: J Rheumatol - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research
Advances in natural products and antibody drugs for SLE: new therapeutic ideas
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune systemic disease with a wide range of clinical symptoms, complex development processes, and uncertain prognosis. The clinical treatment of SLE is mainly based on hormones and immunosuppressants. Research on novel therapy strategies for SLE has flourished in recent years, especially the emergence of new targeted drugs and natural products that can modulate related symptoms. This review discusses the current experience including B-cell targeted drugs (belimumab, tabalumab, blisibimod, atacicept, rituximab, ofatumumab, ocrelizumab, obexelimab, and epratuzumab), T-cell...
Source: Frontiers in Pharmacology - July 10, 2023 Category: Drugs & Pharmacology Source Type: research
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia
This study reports the results of 3 randomized, double-masked, placebo-controlled substudies of abatacept, cenicriviroc, and infliximab plus standard care for COVID-19 pneumonia. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - July 10, 2023 Category: General Medicine Source Type: research
Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting
AbstractThis review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) presented at the 2022 ASH Annual Meeting. The use of innovative agents and regimens, along with the conventional prophylactic approach of combining post-transplant cyclophosphamide and anti-thymocyte globulin, were discussed. The innovative agents and regimens highlighted in this review include abatacept, the first FDA-approved drug for acute GvHD prophylaxis; RGI-2001, which promotes the expansion of regulatory T cells; and cell therapies such as Orca-T and Orca-Q. These advancements provide promising strate...
Source: Experimental Hematology and Oncology - July 7, 2023 Category: Cancer & Oncology Source Type: research
Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
CONCLUSION: We found high heterogeneity among studies comparing rituximab, abatacept, and tocilizumab. On multivariate metaregressions, if the conditions of the RCTs were similar, we estimate that abatacept could increase the chance of reaching an ACR70 response by 2.2-fold compared to tocilizumab.PMID:37415193 | DOI:10.1186/s42358-023-00298-z (Source: Adv Data)
Source: Adv Data - July 6, 2023 Category: Epidemiology Authors: Alisson Pugliesi Amanda Borges de Oliveira Ana Beatrice Oliveira Ricardo Xavier Licia Maria Henrique da Mota Manoel Barros Bertolo Miguel Angel Gonzalez-Gay Gustavo Citera Luiz Sergio Fernandes de Carvalho Source Type: research
Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
CONCLUSION: We found high heterogeneity among studies comparing rituximab, abatacept, and tocilizumab. On multivariate metaregressions, if the conditions of the RCTs were similar, we estimate that abatacept could increase the chance of reaching an ACR70 response by 2.2-fold compared to tocilizumab.PMID:37415193 | DOI:10.1186/s42358-023-00298-z (Source: Adv Data)
Source: Adv Data - July 6, 2023 Category: Epidemiology Authors: Alisson Pugliesi Amanda Borges de Oliveira Ana Beatrice Oliveira Ricardo Xavier Licia Maria Henrique da Mota Manoel Barros Bertolo Miguel Angel Gonzalez-Gay Gustavo Citera Luiz Sergio Fernandes de Carvalho Source Type: research
